• WNT5a/GSK3/β-Catenin Control of FAP Adipogenesis

  2026-08-24

  This study identifies the WNT5a/GSK3/β-catenin axis as a regulator of adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). By combining pharmacological screening, mass cytometry, animal models, and transcriptomic network analysis, the authors connect impaired WNT5a signaling with fatty degeneration and show that GSK3 inhibition can suppress FAP adipogenesis while improving support for muscle regeneration.

• Stable Yeast Expression of Exendin-4 for Type 2 Diabetes

  2026-08-23

  A 2024 Frontiers in Systems Biology study developed recombinant expression models for Exendin-4 in Escherichia coli and Saccharomyces cerevisiae, with chromosomally integrated yeast producing immunoassay-detectable protein at the expected size. The work is an early synthetic-biology feasibility study: it supports a potentially local and lower-cost production strategy, but does not yet establish peptide yield, receptor activity, oral delivery, or therapeutic efficacy.

• Autophagy, Periostin, and Cementoblast Mineralization

  2026-08-22

  The reference study identifies autophagy as a functional mediator of cementoblast mineralization under compressive force, rather than merely a stress-associated cell process. Its data connect periostin to Wnt transcriptional activity through β-catenin ubiquitination, providing a mechanistic framework for understanding cementum repair and orthodontic root resorption.

• TH287 MTH1 Inhibitor: An Assay Design Guide

  2026-08-21

  Explore how TH287, a potent MTH1 inhibitor, converts oxidized nucleotide stress into measurable cancer-cell death. This assay-centered guide explains radiation timing, orthogonal readouts, controls, and the practical significance of recent CRPC findings.

• AICAR Workflows for AMPK Metabolic Research

  2026-08-20

  AICAR provides a practical pharmacological benchmark for AMPK activation in energy metabolism, inflammation, and hepatic stellate cell assays. This workflow connects the compound to a recent MAFLD fibrosis study while emphasizing dose selection, lipid-droplet readouts, and troubleshooting limits.

• TH287 MTH1 Inhibitor for Cancer Radiosensitization

  2026-08-20

  TH287 converts oxidized nucleotide stress into a measurable cancer-cell vulnerability and provides a practical way to test radiosensitization in CRPC models. This workflow emphasizes treatment sequence, orthogonal DNA-damage readouts, and troubleshooting beyond a single viability endpoint.

• TH287 MTH1 Inhibitor: Assay Design and Radiosensitization

  2026-08-19

  TH287 is a high-potency MTH1 inhibitor that converts oxidized nucleotide stress into a measurable cancer-cell vulnerability. This guide moves beyond headline radiosensitization results to explain timing, controls, orthogonal readouts, formulation, and translational limitations.

• DRB for Transcriptional Elongation Assays

  2026-08-19

  DRB provides a rapid pharmacological way to probe transcriptional output, CDK-dependent regulation, and RNA-processing consequences in cell-based assays. This guide connects its benchmark activity with practical workflows for stem-cell fate studies, virology experiments, and troubleshooting of solvent, timing, and selectivity problems.

• Tariquidar in High-Viscosity Chemoresistance Models

  2026-08-18

  Tariquidar (XR9576) helps determine whether mechanically induced chemotherapy resistance is driven by P-glycoprotein efflux rather than by nonspecific loss of drug activity. This workflow combines viscosity-controlled models, fluorescent transporter assays, and chemoresistance endpoints for more interpretable cancer drug-resistance research.

• Omeprazole A2845: Practical Research Guidance

  2026-08-18

  Omeprazole (SKU A2845) is a research-grade H+,K+-ATPase inhibitor for controlled studies of gastric acid secretion, proton pump inhibition, and antiulcer activity. It is intended for laboratory research only, with DMSO-based preparation and solid storage at -20 °C; it should not be used for diagnostic, clinical, or medical purposes.

• LY2886721 BACE Inhibitor Research Workflows

  2026-08-17

  LY2886721 supports controlled BACE1 enzyme inhibition across biochemical, neuronal, and transgenic-mouse workflows. Its strongest use-case is pairing amyloid beta reduction with synaptic-function measurements to identify exposure levels that alter APP processing without overinterpreting a single biomarker.

• nPEC for Dual-Loaded Liposome Encapsulation

  2026-08-17

  Yuan and colleagues compared six separation strategies for measuring the encapsulation efficiency of dual-loaded liposomes containing hydrophilic and lipophilic drugs. Their validated nanoparticle exclusion chromatography approach enabled simultaneous online HPLC analysis and offered a broadly applicable alternative to more laborious or formulation-specific methods.

• Cisapride in iPSC-CM Cardiotoxicity Workflows

  2026-08-16

  Cisapride, also known as R 51619, connects 5-HT4 receptor biology with hERG channel inhibition in practical cardiac safety workflows. Use it as a mechanistic challenge compound for iPSC-derived cardiomyocyte imaging, electrophysiology, and orthogonal cardiac arrhythmia research.

• Octenidine Dihydrochloride Research Workflows

  2026-08-15

  Build reproducible antimicrobial screens around octenidine dihydrochloride with controlled stock preparation, membrane-disruption readouts, and matrix-aware troubleshooting. The workflow also shows how recent gemini quaternary ammonium research can guide bacterial, biofilm, fungal, and carefully bounded comparative assays.

• HyperScript™ Reverse Transcriptase for qPCR

  2026-08-14

  HyperScript™ Reverse Transcriptase is designed for difficult RNA-to-cDNA workflows, including structured transcripts, long targets, and low-copy RNA detection. This practical guide connects its thermal stability and reduced RNase H activity to RT-qPCR assay design, using hepatocellular carcinoma research as an applied example.

8624 records 1/575 page Next 12345 下5页 Last page